MoonLake Immunotherapeutics (MLTX)
Health Care ยท Pharmaceutical Preparations
MoonLake Immunotherapeutics (MLTX) is listed on Nasdaq, where its shares have traded since April 6, 2022. SentiSense covers MoonLake Immunotherapeutics in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Jorge Santos da Silva is its chief executive officer. The company reports 130 employees, and its corporate website is www.moonlaketx.com.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Latest reported results
MoonLake Immunotherapeutics reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 168 institutions reported holding MLTX, with 73.2 million shares worth $1.4 billion in aggregate. The largest reported holders were Bvf Inc/IL, Deep Track Capital and T. Rowe Price. Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
More on MLTX
- MLTX sentiment: whether news and social coverage of MoonLake Immunotherapeutics leans bullish or bearish, and the stories driving it.
- MLTX ownership: all 168 reporting institutions, plus insider and congressional trades.
- MLTX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for MoonLake Immunotherapeutics: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases.
What sector is MLTX in?
SentiSense classifies MoonLake Immunotherapeutics in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does MLTX stock trade?
MoonLake Immunotherapeutics (MLTX) is listed on Nasdaq, where its shares have traded since April 6, 2022.
Who is the CEO of MoonLake Immunotherapeutics?
Jorge Santos da Silva is the chief executive officer of MoonLake Immunotherapeutics.